Browse > Article

Preparation and Biodistribution of Re-188-Sulfur Colloid Suspension in Lipiodol  

Kim, Young-Ju (Department of Nuclear Medicine, Seoul National University College of Medicine)
Jeong, Jae-Min (Department of Nuclear Medicine, Seoul National University College of Medicine)
Kim, Seok-Ki (Department of Nuclear Medicine, National Cancer Center)
Son, Mi-Won (Research Laboratories, Dong-A Pharm. Co., Ltd.)
Lee, Dong-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine)
Chung, June-Key (Department of Nuclear Medicine, Seoul National University College of Medicine)
Lee, Myung-Chul (Department of Nuclear Medicine, Seoul National University College of Medicine)
Publication Information
The Korean Journal of Nuclear Medicine / v.37, no.5, 2003 , pp. 301-307 More about this Journal
Abstract
Purpose: Lipiodol is used for targeting liver cancers by administrating through the hepatic artery. In the present study, feasibility of Re-188-sulfur colloid suspension in lipiodol as a liver cancer targeting agent was investigated. Materials and Methods: Re-188-sulfur colloid was prepared, harvested by centrifugation, washed with organic solvent and then suspended into lipiodol. Biodistribution of Re-188-sulfur colloid in normal saline and its suspension in lipiodol in mice after 1 hr of injection through the tail vein were investigated. Biodistribution and autoradiography of tumor-hearing liver was acquired after 5 min post-injection into left ventricle of the tumor-inoculated rats. Results: After 1 hr of injection with Re-188-sulfur colloid suspensiob in lipiodol through the tail vein in normal mice (n=3), the uptakes in the liver and lung were $5.2{\pm}0.7\;and\;91.0{\pm}1.7%$ ID/organ, respectively. After 5 min of injection with Re-188-sulfur colloid suspention in lipiodol through the left ventricle in the tumor-inoculated rats (n=4), uptakes in the normal liver, hepatoma, and lung were $0.41{\pm}0.28,\;1.88{\pm}1.57,\;and\;1.65{\pm}1.54%$ ID/organ, respectively. And autoradiography of hepatoma showed increased uptake than normal liver tissues. Conclusion: Re-188-sulfur colloid suspension in lipiodol injected through the artery shows higher uptake in the hepatoma than normal liver tissue that indicates the feasibility as a new radiopharmaceutical for therapy of hepatoma.
Keywords
Re-188-Sulfur Colloid; Lipiodol; Hepatoma; Biodistribution;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lencieoni R, Vignali C, Caramella D, Cioni R, Mazzeo S, Bartolozzi C. Transcatheter arterial embolization followed by percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 1994;17:70-5
2 Park CH, Yoo HS, Lee JT, Kim DI. Iodine-131-labeled lipiodol retention within hepatic cavernous hemangioma. Radiology 1987;163: 283-4   DOI   PUBMED
3 Chen MN, Wang SJ, Kao CH, Tsai ZT. A column method for lipiodol labeling with yttrium-90 [abstract]. J Nucl Med 1994;35: 241p
4 Yu J, Hafeli UO, Sands M, Dong Y. 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer. Appl Radiat Isot 2003;58: 567-73   DOI   ScienceOn
5 Lee Y-S, Jeong JM, Kim YJ, Chung JW, Park JH, Suh Y-G, et al. Sythesis of 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23: 237-42   DOI   ScienceOn
6 Wang S-J, Lin W-Y, Chen M-N, Hsieh B-T, Shen L-H, Tsai Z-T, et al. Radiolabeling of lipiodol with generator-produced 188Re for hepartic tumor therapy. Appl Radiat Isot 1996;47: 267-71   DOI   ScienceOn
7 Madsen MT, Park CH, Takur ML. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma, J Nucl Med 1988;29: 1038-44   PUBMED
8 Jeong JM, Kim YJ, Lee YS, Ko JI,, Son M, Lee DS, et al. Lipiodol solution of a lipiodol agent, $^188$Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28: 197-204   DOI   ScienceOn
9 Nakajo M, Kobayashi H, Shimabukuro K, Shirono K, Sakata H, Taguchi M, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988;29: 1066-77   PUBMED
10 Wang S-J, Lin W-Y, Hsieh B-T, Shen L-H, Tsai Z-T, Ting G, et al. Rhenium-188 sulphur colloid as a radiation synovectomy agent. Eur J Nucl Med 1995;22: 505-7   DOI   PUBMED   ScienceOn
11 Trinchet J-C, Rached AA, Beaugrand M, Mathieu D, Cheveret S, Chastang C. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. New Engl J Med 1995;332: 1256-61   DOI   ScienceOn
12 Wang S-J, Lin W-Y, Chen M-N, Shen L-H, Tsai Z-T, Ting G. Preparation and biodistribution of yttrium-90 lipiodol in rats following hepartic arterial injection. Eur J Nucl Med 1995;22: 233-6   DOI   ScienceOn
13 Venkatesan PP, Shorkroff S, Zalutsky MR, Sledge CB. Rhenium heptasulfide: a potential carrier system for radiation synovectomy. Nucl Med Biol 1990;17: 357-62
14 Kim YJ, Jeong JM, Chang YS, Lee YJ, Lee DS Chung J-K, et al. Preparation and biodistribution of Re-188 sulfur colloid, Koraen J Nucl Med 1998;32:298-304
15 Wang S-J, Lin W-Y, Chen M-N, Hsieh B-T, Shen L-H, Tsai Z-T, et al. Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med 1996;23: 13-7   DOI   ScienceOn
16 Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170: 783-6   PUBMED
17 Park CH, Suh JH, Yoo HS. Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Clin Nucl Med 1986;11:514-7   DOI   PUBMED
18 Yoo HS, Suh JH, Lee JT, Kim DI, Park CY, Kim BS, et al. Therapeutic feasibility study and clinical trial of intrahepatic I-131-lipiodol on patients with hepatocellular carcinoma. Korean J Nucl Med 1986;20: 61-71